319 related articles for article (PubMed ID: 35854236)
1. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
2. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ; Toita T; Wu X; Vázquez Limón JC; Tarnawski R; Mandai M; Shapira-Frommer R; Mahantshetty U; Del Pilar Estevez-Diz M; Zhou Q; Limaye S; Godinez FJR; Oppermann Kussler C; Varga S; Valdiviezo N; Aoki D; Leiva M; Lee JY; Sulay R; Kreynina Y; Cheng WF; Rey F; Rong Y; Ke G; Wildsmith S; Lloyd A; Dry H; Tablante Nunes A; Mayadev J
Lancet Oncol; 2023 Dec; 24(12):1334-1348. PubMed ID: 38039991
[TBL] [Abstract][Full Text] [Related]
4. Combined pretreatment with
Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
[TBL] [Abstract][Full Text] [Related]
5. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
6. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
Zhu Y; Wen J; Li Q; Chen B; Zhao L; Liu S; Yang Y; Wang S; Lv Y; Li J; Zhang L; Hu Y; Liu M; Xi M
Lancet Oncol; 2023 Apr; 24(4):371-382. PubMed ID: 36990609
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
Liu C; Ran X; Wang Z; Zhang K
Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
[TBL] [Abstract][Full Text] [Related]
10. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
Okonogi N; Usui H; Murata K; Hori M; Kurokawa T; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Hasegawa S; Yamada S; Hanaoka H; Shozu M; Tsuji H
BMJ Open; 2022 Mar; 12(3):e056424. PubMed ID: 35236732
[TBL] [Abstract][Full Text] [Related]
12. PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Tuyaerts S; Van Nuffel AMT; Naert E; Van Dam PA; Vuylsteke P; De Caluwé A; Aspeslagh S; Dirix P; Lippens L; De Jaeghere E; Amant F; Vandecasteele K; Denys H
BMC Cancer; 2019 May; 19(1):506. PubMed ID: 31138229
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
14. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
[TBL] [Abstract][Full Text] [Related]
15. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
[TBL] [Abstract][Full Text] [Related]
18. A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
He ZY; Li HY; Yan J; Li SJ; Li DC; Liang ZZ
Trials; 2022 Jul; 23(1):556. PubMed ID: 35804452
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
Umayahara K; Takekuma M; Hirashima Y; Noda SE; Ohno T; Miyagi E; Hirahara F; Hirata E; Kondo E; Tabata T; Nagai Y; Aoki Y; Wakatsuki M; Takeuchi M; Toita T; Takeshima N; Takizawa K
Gynecol Oncol; 2016 Feb; 140(2):253-8. PubMed ID: 26701414
[TBL] [Abstract][Full Text] [Related]
20. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
